| Literature DB >> 25265271 |
Takeshi Soeki1, Kunihiko Koshiba2, Toshiyuki Niki3, Kenya Kusunose4, Koji Yamaguchi4, Hirotsugu Yamada4, Tetsuzo Wakatsuki4, Michio Shimabukuro5, Kazuo Minakuchi6, Ichiro Kishimoto7, Kenji Kangawa7, Masataka Sata4.
Abstract
Ghrelin is a novel growth hormone (GH)-releasing peptide originally isolated from the stomach. Recently, we have shown that ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. In the present study, we evaluated the effect of ghrelin on autonomic nerve activity in healthy human subjects. An intravenous bolus of human synthetic ghrelin (10μg/kg) was administered to 10 healthy men (mean age, 33 years). Holter monitoring assessment was performed before and during 2h after the ghrelin therapy. The standard deviation of normal RR intervals (SDNN), square root of the mean of the sum of the squares of differences between adjacent RR intervals (rMSSD), high-frequency power (HF), and low-frequency power (LF) were analyzed. Blood samples were also obtained before and after the therapy. A single administration of ghrelin decreased both heart rate and blood pressure. Interestingly, ghrelin significantly decreased the LF and LF/HF ratio of heart rate variability and increased the SDNN, rMSSD, and HF. Ghrelin also elicited a marked increase in circulating GH, but not insulin-like growth factor-1. These data suggest that ghrelin might suppress cardiac sympathetic nerve activity and stimulate cardiac parasympathetic nerve activity.Entities:
Keywords: Autonomic nerve activity; Electrocardiography; Ghrelin; Heart rate variability; Hemodynamics
Mesh:
Substances:
Year: 2014 PMID: 25265271 DOI: 10.1016/j.peptides.2014.09.015
Source DB: PubMed Journal: Peptides ISSN: 0196-9781 Impact factor: 3.750